CD21 positive B cell: A novel target for treatment of multiple sc | 51734
Journal of Clinical and Cellular Immunology

Journal of Clinical and Cellular Immunology
Open Access

ISSN: 2155-9899

CD21 positive B cell: A novel target for treatment of multiple sclerosis

3rd International Conference and Exhibition on Clinical & Cellular Immunology

September 29-October 01, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

Mojtaba Farjam

Accepted Abstracts: J Clin Cell Immunol

Abstract :

Etiologic-based therapy is an ideal pharmacological option to treat or prevent diseases. There is no known etiology for multiple sclerosis (MS); however, environmental risk factors have been suggested to predispose genetically susceptible people to be affected by the disease. One of these risk factors is infection with Epstein-Barr virus (EBV). Eradication of this virus has not been effective in modulation of MS, probably due to being inhabitant in the CD21 (EBV receptor) positive B cells. To eradicate this virus, targeting CD21 on these EBV-infected B cells is hypothesized here. A sequential study plan to test this hypothesis has been suggested too. This study might eventually suggest an effective immunopharmacological strategy to treat MS. Moreover, testing this strategy will help in better clarification of the role of EBV in MS disease triggering and predisposition.

Biography :

Mojtaba Farjam graduated in medicine in 2001 and received a PhD in Pharmacology from Shiraz University of Medical Sciences, Iran. He studied neuroimmune pharmacology of multiple sclerosis as a Research Scholar in Thomas Jefferson Medical College PA, USA in 2012. Currently, he is the Scientific Executive of Fasa Cohort Study, Fasa, Iran and Assistant Professor of Medical Pharmacology in Fasa University of Medical Sciences.